| Style | Citing Format |
|---|---|
| MLA | Kianfar T, et al.. "Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion." Journal of Cardiovascular Pharmacology, vol. 87, no. 3, 2026, pp. 160-172. |
| APA | Kianfar T, Fallah M, Ramezani F, Rakhshan K, Najafzadeh E, Azizi Y (2026). Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion. Journal of Cardiovascular Pharmacology, 87(3), 160-172. |
| Chicago | Kianfar T, Fallah M, Ramezani F, Rakhshan K, Najafzadeh E, Azizi Y. "Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion." Journal of Cardiovascular Pharmacology 87, no. 3 (2026): 160-172. |
| Harvard | Kianfar T et al. (2026) 'Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion', Journal of Cardiovascular Pharmacology, 87(3), pp. 160-172. |
| Vancouver | Kianfar T, Fallah M, Ramezani F, Rakhshan K, Najafzadeh E, Azizi Y. Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion. Journal of Cardiovascular Pharmacology. 2026;87(3):160-172. |
| BibTex | @article{ author = {Kianfar T and Fallah M and Ramezani F and Rakhshan K and Najafzadeh E and Azizi Y}, title = {Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion}, journal = {Journal of Cardiovascular Pharmacology}, volume = {87}, number = {3}, pages = {160-172}, year = {2026} } |
| RIS | TY - JOUR AU - Kianfar T AU - Fallah M AU - Ramezani F AU - Rakhshan K AU - Najafzadeh E AU - Azizi Y TI - Dapagliflozin Reduces Myocardial Injuries Through Modulation of H3k27me3 and Sirt1 in the Male Rat Model of Myocardial Ischemia Reperfusion JO - Journal of Cardiovascular Pharmacology VL - 87 IS - 3 SP - 160 EP - 172 PY - 2026 ER - |